menu

CME: Moving Toward A New Standard of Care: Checkpoint Inhibitors in Advanced Urothelial Cancer

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Moving Toward A New Standard of Care: Checkpoint Inhibitors in Advanced Urothelial Cancer

Moving Toward A New Standard of Care: Checkpoint Inhibitors in Advanced Urothelial Cancer
RestartResume
Learn more about the new immunotherapy agents available for advanced and metastatic urothelial cancer.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. Standard salvage systemic therapies for advanced/metastatic UC, and chemotherapy regimens were associated with modest survival advantage, and significant toxicities; however, the introduction of novel immunotherapy agents has led to rapid changes in the field of UC.

    Dr. John Russell, Director of the Family Medicine Residency at Abington Memorial Hospital, is joined by Dr. Arjun V. Balar, Associate Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center.

  • Learning Objectives

    • Identify and interpret the latest clinical evidence regarding checkpoint inhibitors in advanced/recurrent urothelial cancer and apply to clinical practice;
    • Examine the latest clinical trial data involving combination immunotherapy for advanced/recurrent urothelial cancer;
    • Investigate novel immunotherapy options under development and its implications.
  • Target Audience

    The intended audiences for this activity are physicians and other health care professionals who manage patients with advanced urothelial cancer. 

  • Faculty & Disclosures

    Faculty: 
    Arjun V. Balar, MD
    Associate Professor of Medicine
    Director of the Genitourinary Medical Oncology Program
    Laura and Isaac Perlmutter Cancer Center
    New York University Langone Medical Center
    New York, New York

    Moderator:
    John J. Russell, MD
    Director, Family Medicine Residency Program
    Abington Jefferson Hospital
    Abington, Pennsylvania

    Disclosure of Conflicts of Interest:

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Arjun V. Balar, MD, has disclosed the following relevant financial relationships:
    He served as an advisory board member for AstraZeneca, Genentech and Merck. 
    He also served as a consultant for Incyte, Merck and Pfizer and a speaker for Merck, AstraZeneca, Genentech and Pfizer.

    John J. Russell, MD (host) has disclosed the following relevant financial relationships. He served as a speaker and advisory board member for Sanofi.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    • Susan Tyler, MEd, CMP, CHCP, CME Director, has nothing to disclose.
    • Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    • Jennifer Holzberger, Program Coordinator, has nothing to disclose.
    • Otto Ratz, MD, has nothing to disclose.
    • Christina Culbert, MSc, has nothing to disclose.
  • Accreditation and Credit Designation Statements

    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Merck & Co., Inc. and AstraZeneca.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instruction for Participation

    There are no fees for participating in and receiving CME credit for this online activity. During the period of September 25, 2018 to September 24, 2019, participants must 1) read the CME information, including the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score of 70% and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post test and evaluation will have a statement of credit made available immediately.

  • Additional Resources

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.